Liraglutide: A review of its use in the management of type 2 diabetes mellitus

Drugs

Volumn 71, Issue 17, 2011, Pages 2347-2373

  Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Liraglutide; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ATORVASTATIN; DIGOXIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GRISEOFULVIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LISINOPRIL; METFORMIN; METFORMIN PLUS PIOGLITAZONE; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

ADD ON THERAPY; ANOREXIA; AREA UNDER THE CURVE; CARDIOTOXICITY; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE RASH; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PATIENT SATISFACTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 81155154236     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208110-000000000-00000     Document Type: Review

References (106)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53 (Pubitemid 38579764)
2. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86 (1): 44-57
3. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a metaanalysis of randomised controlled trials. Lancet 2009; 373 (9677): 1765-72
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53
5. Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs 2009 Oct 1; 69 (14): 1985-2004
6. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus: current and emerging agents. Drugs 2011 Sep 10; 71 (13): 1675-88
7. European Medicines Agency. Victoza (liraglutide): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/001026/WC 500050017.pdf [Accessed 2011 Nov 2]
8. Novo Nordisk Inc. Liraglutide US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/ 022341s004lbl.pdf [Accessed 2011 Nov 2]
9. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase I II, double-blind, parallel-treatment trial. Lancet 2009 Feb 7; 373 (9662): 473-81
10. Garber A, Henry RR, Ratner R, et al. Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13 (4): 348-56
11. Marre M, Shaw J, Brandle M, et al. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009 Mar; 26 (3): 268-78
12. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2-study. Diabetes Care 2009; 32 (1): 84-90
13. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 Jul 4; 374 (9683): 39-47
14. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrin Metab 2011 Jun; 96 (6): 1695-702
15. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009 Jul; 32 (7): 1224-30
16. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009 Oct; 52 (10): 2046-55
17. Russell-Jones D, Sesti G, Garber A, et al. A meta-analysis of weight loss incurred by liraglutide in patients with type 2 diabetes with and without gastro-intestinal side-effects [abstract]. Diabetologia 2010; 53 Suppl.: S332
18. Knudsen L, Tang-Christiansen M, Jelsing J, et al. Liraglutide: short-lived effect on gastric emptying-longlasting effects on body-weight. [abstract]. Diabetologia 2010; 53 Suppl. 1: S342
19. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010 Apr 24; 375 (9724): 1447-56
20. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65 (4): 397-407
21. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 2011; 13 (1): 81-8
22. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010 Apr; 12 (4): 341-7
23. NauckM, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009 May; 121 (3): 5-15
24. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010 May; 26 (5): 1013-22
25. Mari A, Degn K, Brock B, et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on betacell function in normal living conditions. Diabetes Care 2007 Aug; 30 (8): 2032-3 (Pubitemid 47219415)
26. Juhl C, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002 Feb; 51 (2): 424-9 (Pubitemid 34764798)
27. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009 Dec; 11 (12): 1163-72
28. Colagiuri S, Frid A, Zdravkovic M, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes [abstract no. 899]. Diabetologia 2008 Sep; 51 Suppl. 1: S360
29. Dear AE, Liu H, Knudsen LB, et al. Liraglutide inhibits hyperglycaemia induced expression of PAI-1 and vascular adhesion molecules in an in vitro model of endothelial cell dysfunction [abstract no. 893]. Diabetologia 2008 Sep; 51 Suppl. 1: S356
30. Sprenger C, Khutoryansky N, Chatterjee DJ, et al. Liraglutide does not affect cardiac repolarization [abstract no. 2103-PO]. Diabetes 2008 Jun; 57 Suppl. 1: 581
31. Shimoda M, Kanda Y, Tawaramoto K, et al. The oncedaily human GLP-1 analogue liraglutide preserves pancreatic beta cells in diabetic db/db mice through both acute and chronic action mechanisms [abstract no. 511]. Diabetologia 2008 Sep; 51 Suppl. 1: S210
32. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005 May 6; 330 (2): 577-84 (Pubitemid 40417684)
33. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009 Apr; 58 (4): 975-83
34. Flint A, Hindsberger C. The relationship between pharmacokinetics of the once-daily human GLP-1 analog liraglutide and pharmacodynamic effects on glycemia, gastric emptying and energy intake [abstract no. 159O-159P]. American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25-29; Orlando (FL)
35. Flint A, Kapitza C, Hindsberger C, et al. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011 Mar; 28 (3): 213-26
36. Flint A, Kapitza C, Hindsberger C, et al. The once-daily human GLP-1 analogue liraglutide decreases postprandial hunger and energy intake [abstract no. 555-P]. Diabetes 2008 Jun; 57 Suppl. 1: A165
37. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a-and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53 (5): 1187-94 (Pubitemid 38569002)
38. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004 Aug; 27 (8): 1915-21 (Pubitemid 38989232)
39. Nauck MA, El-Ouaghlidi A, Hompesch M, et al. No impairment of hypoglycaemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with type 2-diabetes [abstract no. 824]. Diabetologia 2003; 46 Suppl. 2: A285
40. Horowitz M, Flint A, Doran S, et al. Effects of the oncedaily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes [abstract no. 889]. Diabetologia 2008 Sep; 51 Suppl. 1: S355
41. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a oncedaily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008 Feb; 25 (2): 152-6 (Pubitemid 351293400)
42. Plutsky J, Garber A, Falahati A, et al. Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis [abstract 0542]. International Diabetes Federation 20th World Diabetes Congress; 2009 Oct 18-22; Montreal (QC)
43. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 Jun; 30 (6): 1608-10 (Pubitemid 46871185)
44. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dosedependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008 Aug; 81 (2): 161-8
45. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003 Jul; 52 (7): 1786-91 (Pubitemid 36792471)
46. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008 Sep; 25 (9): 1129-31
47. Raun K, von Voss P, Knudsen LB. Liraglutide, a oncedaily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007 Jul; 15 (7): 1710-6 (Pubitemid 47264950)
48. Knudsen LB. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-Cells causing calcitonin release and C-cell proliferation. Endocrinology 2010 Apr; 151 (4): 1473-86
49. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011 Mar; 96 (3): 853-60
50. Vilsboll T. The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009 Dec; 11 Suppl. 3: 11-8
51. Garber AJ, Marre M, Nauck MA, et al. The efficacy of liraglutide is not impacted in subjects positive for anti-liraglutide antibodies: a pooled analysis [abstract]. 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension; 2010 May 13-16; Prague
52. Raun K, von Voss P, Gotfredsen CF, et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007 Jan; 56 (1): 8-15
53. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67 (6): 935-54 (Pubitemid 46607392)
54. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009 Nov; 49 (11): 1353-62
55. Davidson JA, Brett J, Falahati A, et al. Mild renal impairment and the efficacy and safety of liraglutide. Endocrine Practice 2011 May 30; 17 (3): 345-55
56. Steensgaard DB, Thomsen JK, Olsen HB, et al. The molecular basis for the delayed absorption of the oncedaily human GLP-1 analogue, liraglutide [abstract no. 552-P]. Diabetes 2008; 57 Suppl. 1: A164
57. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 2006; 26 (3): 360-74 (Pubitemid 43334676)
58. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43 (9): 1664-9 (Pubitemid 30304999)
59. Elbrond B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a singledose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002 Aug; 25 (8): 1398-404 (Pubitemid 41071152)
60. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002 Feb; 45 (2): 195-202 (Pubitemid 34208381)
61. Watson E, Jonker DM, Jacobsen LV, et al. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twicedaily exenatide. J Clin Pharmacol 2010 Aug; 50 (8): 886-94
62. Irie S, Matsumura Y, Zdravkovic M, et al. Tolerability, pharmacokinetics and pharmacodynamics of the oncedaily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther 2008 Jun; 46 (6): 273-9 (Pubitemid 351890729)
63. Kapitza C, Zdravkovic M, Zijlstra E, et al. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol 2011 Jun; 51 (6): 951-5
64. Jacobsen LV, Hindsberger C, Robson R, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009 Dec; 68 (6): 898-905
65. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol 2010 Dec; 70 (6): 807-14
66. Zdravkovic M, Ekblom M, Brondsted L, et al. The effect of liraglutide on the absorption pharmacokinetics of concomitant oral drugs with different solubility and permeability properties in healthy subjects [abstract no. 890]. Diabetologia 2008 Sep; 51 Suppl. 1: S355
67. Kapitza C, Zdravkovic M, Hindsberger C, et al. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Adv Ther 2011 Aug; 28 (8): 650-60
68. Morrow L, Hompesch M, Guthrie H, et al. Coadministration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab 2011; 13 (1): 75-80
69. Novo Nordisk. Positive opinion on the usage of Levemir(insulin detemir) as add-on therapy to Victoza(liraglutide) in people with type 2 diabetes [online]. Available from URL: http://www.novonordisk.com/include/asp/exe-news- attachment.pdf [Accessed 2011 Nov 2]
70. Buse JB, Sesti G, Schmidt WE, et al. Switching to oncedaily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010 Jun; 33 (6): 1300-3
71. Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Invest 2011 Aug; 2 (4): 280-6
72. Kaku K, Rasmussen MF, Nishida T, et al. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Invest. Epub 2011 May 19
73. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004 Jun; 27 (6): 1335-42 (Pubitemid 38679980)
74. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005 Aug; 22 (8): 1016-23 (Pubitemid 41025998)
75. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009 Jan; 32 Suppl. 1: S13-61
76. American Association of Clinical Endocrinologists Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl. 1: 3-68
77. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 Jun; 23 (6): 579-93
78. Matthews DR, Marre M, Le-Thi TD, et al. Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes [abstract no. 892]. Diabetologia 2008 Sep; 51 Suppl. 1: S356
79. Davies M, Pratley R, Montanya E, et al. Liraglutide reduces A1c to a greater extent than sitagliptin regardless of baseline A1c levels [abstract no. 57]. American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25-29; Orlando (FL)
80. Hermansen K, Kolotkin RL, Hammer M, et al. Patientreported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes 2010 Jul; 4 (2): 113-7
81. Davies M, Pratley R, Hammer M, et al. Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011; 28 (3): 333-7
82. Bode BW, Testa MA, Magwire M, et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2010 Jul; 12 (7): 604-12
83. YadavD, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006 Nov; 33 (4): 323-30
84. Fagenholz PJ, Fernandez-del Castillo C, Harris NS, et al. Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas 2007; 35: 302-7 (Pubitemid 350307371)
85. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009 May; 32 (5): 834-8
86. Frey CF, Zhou H, Harvey DJ, et al. The incidence and case-fatality rates of acute biliary, alcoholic, and idiopathic pancreatitis in California, 1994-2001. Pancreas 2006; 33: 336-44 (Pubitemid 44690721)
87. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011 May; 27 (5): 897-906
88. Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010; 32 (10): 1756-67
89. Valentine WJ, Palmer AJ, Lammert M, et al. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. Epub 2011 Oct 19
90. Ivanova A, Petrova G, Wrona W, et al. Economic evaluation of liraglutide vs. rosiglitazone or exenatide for type 2 diabetes mellitus in Bulgaria [abstract no. PDB61]. International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress; 2010 Nov 6-9; Prague
91. Schlander M, Mentrup S, Lund N. Incretin-therapy in addition to metformin and/or sulfonylurea for type 2 diabetes mellitus (T2dm): cost-effectiveness of liraglutide versus exenatide from the perspective of the German Statutory Health Insurance (SHI) [abstract no. PDB42]. International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress; 2010 Nov 6-9; Prague
92. Schlander M, Mentrup S, Lund N. Addition of incretintherapy to metformin in type-2-diabetes mellitus (T2dm): cost-effectiveness of liraglutide versus sitagliptin from the perspective of the German statutory health insurance (SHI) [abstract PDB38]. International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress; 2010 Nov 6-9; Prague
93. Sullivan SD, Alfonso-Cristancho R, Conner C, et al. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy 2009 Nov 1; 29 (11): 1280-8
94. Sullivan SD, Alfonso-Cristancho R, Conner C, et al. Longterm outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol 2009 Feb; 8 (12): 12
95. Jendle J, Torffvit O, Ridderstrale M, et al. Patient willingness-to-pay for liraglutide and glimepiride based on head-to-head clinical trial results [abstract no. P-1312]. American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25-29; Orlando (FL)
96. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203
97. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim [media release; online]. Available fromURL: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/ 2010/09/WC500096996.pdf [Accessed 2011 Nov 2]
98. European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/Press-release/2011/07/WC500109176.pdf [Accessed 2011 Nov 2]
99. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control [published erratum appears in Endocr Pract 2009; 15 (7): 768-70]. Endocr Pract 2009; 15 (6): 540-59
100. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. Am J Manag Care 2010 Aug; 16 (7 Suppl.): S187-194
101. Gallwitz B, Vaag A, Falahati A, et al. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010 Jan; 64 (2): 267-76
102. Zinman B, Colagiuri S, Madsbad S, et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: meta-Analysis of six phase 3 trials [abstract no. 1894]. American Diabetes Association (ADA) 70th Scientific Sessions; 2010 Jun 25-29; Orlando (FL)
103. Schmitz O, Russell-Jones D, Shaw J, et al. Liraglutide, a human GLP-1 analogue, reduces bodyweight in subjects with type 2 diabetes, irrespective of body mass index at baseline [abstract no. 888]. Diabetologia 2008 Sep; 51 Suppl. 1: S354
104. National Institute for Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus [online]. Available from URL: http://www.nice.org.uk/TA203 [Accessed 2011 Nov 2]
105. Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374 (9701): 1606-16
106. Wadden T. Liraglutide provides weight maintenance and additional weight loss after low calorie diet-induced weight loss in obese subjects without diabetes: the SCALE maintenance study [abstract no. 1859-P]. The American Diabetes Association (ADA) 71st Scientific Sessions; 2011 Jun 24-28; San Diego (CA)